お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:心房細動:市場スポットライト
市場調査レポート
商品コード
987740

心房細動:市場スポットライト

Market Spotlight: Atrial Fibrillation

出版日: | 発行: Datamonitor Healthcare | ページ情報: 英文 49 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.72円
心房細動:市場スポットライト
出版日: 2021年01月07日
発行: Datamonitor Healthcare
ページ情報: 英文 49 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界において心房細動の症例数は、2018年に約4,720万件であると推計され、その数は2027年には5,670万件に増加すると予測されています。

当レポートは、心房細動市場について調査しており、主要医薬品とパイプライン製品、臨床試験、最近のイベントとアナリストの見解、規制イベント、成功性、10年間の疾患有病率予測、収益予測などの情報を提供しています。

目次

内容

概要

要点

疾患の背景

  • 定義
  • 危険因子
  • 診断
  • 患者のセグメンテーション

治療

  • レート制御
  • リズムコントロール
  • 血栓塞栓症を予防するための薬剤

疫学

市販薬

  • 心房細動/粗動

SPAF

パイプライン薬

  • 心房細動/粗動

SPAF

最近の出来事とアナリストの見解

  • 心房細動/粗動用ブリナベス(2019年12月24日)
  • 心房細動/粗動用ブリナベス(2019年12月10日)
  • 心房細動/粗動用ブリナベス(2019年12月6日)

主要規制イベント

  • Biotronik:BiomonitorIIIm注射用心臓モニターへ温度検知の追加
  • 英国NICE:14日間の携帯型心臓モニタリング技術の暫定資金を支援
  • Accord:XareltoのライバルにEU全体で最初の承認取得
  • Fitbit:Appleに対抗するECGアプリのFDA認可、CEマークの取得
  • LifeSignals:米国FDAからECG遠隔監視プラットフォームの販売許可を取得
  • FDA:Ekoの心臓の状態を検出するAIアルゴリズムの認可
  • 米国FDA:クリアされた心臓の状態を検出するためのEkoのAIアルゴリズム
  • Medtronic:脳卒中患者の埋め込み型モニターに関する英国のNICE決定での勝利、およびBiotronikとAbbottの敗北

成功の確率

  • 心房細動/粗動

SPAF

収益機会

臨床試験の情勢

  • ステータス別のスポンサー
  • フェーズ別のスポンサー
  • 最近のイベント

参考文献

  • 処方情報

付録

図のリスト

表のリスト

目次
Product Code: DMKC0209060

This Market Spotlight report covers the Atrial Fibrillation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2018, there were approximately 47.2 million prevalent cases of atrial fibrillation worldwide, and forecasts that number to increase to 56.7 million prevalent cases by 2027.

The approved drugs in the atrial fibrillation/flutter space focus on targets such as beta adrenergic receptors, alpha adrenergic receptors, potassium channels, sodium channels, and calcium channel. The majority of marketed drugs are administered via the intravenous or oral routes, with only one product being available in a transdermal formulation.

The approved drugs in the stroke prevention in atrial fibrillation (SPAF) space focus on targets such as coagulation factor X, adenosine diphosphate P2Y12 receptor, and thrombin (coagulation factor IIa). All of the marketed drugs for SPAF are administered via the oral route.

The majority of industry-sponsored drugs in active clinical development for atrial fibrillation/flutter are in Phase II, with one drug in the NDA/BLA phase.

Therapies in development for atrial fibrillation/flutter focus on targets such as potassium channels, sodium channels, and beta adrenergic receptors. The majority of these drugs are administered via the oral route, with the remainder being tested in intravenous and inhaled formulations.

The only industry-sponsored drug in active clinical development for SPAF is in Phase II.

The only therapy in development for SPAF targets coagulation factor XI. It is administered via the subcutaneous route. The overall likelihood of approval of a Phase I atrial fibrillation/flutter asset is 2.5%, and the average probability a drug advances from Phase III is 60%. Drugs, on average, take 12.1 years from Phase I to approval, compared to 10.1 years in the overall cardiovascular space.

The overall likelihood of approval of a Phase I SPAF asset is 9.8%, and the average probability a drug advances from Phase III is 85.7%. Drugs, on average, take 6.2 years from Phase I to approval, compared to 9.3 years in the overall hematology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for atrial fibrillation have been in the late phases of development, with 76% of trials in Phase III-IV, and only 24% in Phase I-II.

The US leads in terms of the number of atrial fibrillation clinical trials globally. Germany leads the major European markets, while South Korea has the top spot in Asia.

Clinical trial activity in the atrial fibrillation space is dominated by completed trials. Bayer has the highest number of completed clinical trials for atrial fibrillation, with 44 trials.

Bayer leads industry sponsors with the highest overall number of clinical trials for atrial fibrillation, followed by Johnson & Johnson.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Definition
  • Risk factors
  • Diagnosis
  • Patient segmentation

TREATMENT

  • Rate control strategy
  • Rhythm control strategy
  • Medications to prevent thromboembolism

EPIDEMIOLOGY

MARKETED DRUGS

  • Atrial fibrillation/flutter

SPAF

PIPELINE DRUGS

  • Atrial fibrillation/flutter

SPAF

RECENT EVENTS AND ANALYST OPINION

  • Brinavess for Atrial Fibrillation/Flutter (December 24, 2019)
  • Brinavess for Atrial Fibrillation/Flutter (December 10, 2019)
  • Brinavess for Atrial Fibrillation/Flutter (December 6, 2019)

KEY REGULATORY EVENTS

  • Biotronik Adds Temperature Sensing To Biomonitor IIIm Injectable Cardiac Monitor
  • UK's NICE Backs Interim Funding For 14-Day Ambulatory Heart Monitoring Tech
  • Accord Gets First EU-Wide Nod For Xarelto Rival
  • Fitbit Receives FDA Clearance, CE Mark For ECG App To Rival Apple
  • LifeSignals Receives US FDA Clearance To Market ECG Remote Monitoring Platform
  • FDA Clears Medtronic's And Boston Scientific's Remote Cardiac Monitors, Approves Abbott's Bluetooth-Compatible ICDs
  • Eko's AI Algorithm To Detect Heart Conditions Cleared By US FDA
  • Medtronic Wins In England's NICE Decision On Implantable Monitors For Stroke Patients; Biotronik And Abbott Lose

PROBABILITY OF SUCCESS

  • Atrial fibrillation/flutter

SPAF

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of atrial fibrillation, 2018-27
  • Figure 2: Overview of pipeline drugs for atrial fibrillation/flutter in the US
  • Figure 3: Pipeline drugs for atrial fibrillation/flutter, by company
  • Figure 4: Pipeline drugs for atrial fibrillation/flutter, by drug type
  • Figure 5: Pipeline drugs for atrial fibrillation/flutter, by classification
  • Figure 6: Overview of pipeline drugs for SPAF in the US
  • Figure 7: Pipeline drugs for SPAF, by company
  • Figure 8: Pipeline drugs for SPAF, by drug type
  • Figure 9: Pipeline drugs for SPAF, by classification
  • Figure 10: Probability of success in the atrial fibrillation/flutter pipeline
  • Figure 11: Probability of success in the SPAF pipeline
  • Figure 12: Clinical trials in atrial fibrillation
  • Figure 13: Top 10 drugs for clinical trials in atrial fibrillation
  • Figure 14: Top 10 companies for clinical trials in atrial fibrillation
  • Figure 15: Trial locations in atrial fibrillation
  • Figure 16: Atrial fibrillation trials status
  • Figure 17: Atrial fibrillation trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of atrial fibrillation, 2018-27
  • Table 2: Marketed drugs for atrial fibrillation/flutter
  • Table 3: Marketed drugs for SPAF
  • Table 4: Pipeline drugs for atrial fibrillation/flutter in the US
  • Table 5: Pipeline drugs for SPAF in the US
  • Table 6: Brinavess for Atrial Fibrillation/Flutter (December 24, 2019)
  • Table 7: Brinavess for Atrial Fibrillation/Flutter (December 10, 2019)
  • Table 8: Brinavess for Atrial Fibrillation/Flutter (December 6, 2019)
  • Table 9: Historical global sales, by drug ($m), 2015-19
  • Table 10: Forecasted global sales, by drug ($m), 2021-25
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.